Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics Reports Uptick in Q3 Revenues

NEW YORK, Nov. 12 (GenomeWeb News) – Paradigm Genetics today reported $6 million in revenues for the third quarter of 2003, up slightly from the $5.2 million in revenues for the same period last year.

The company’s net losses decreased to $2.2 million, from $3.9 million in the year-ago quarter.

R&D expenses came to $6.2 million, compared to $6.0 million for the same period last year.

As of Sept. 30, the company had $9.9 million in cash, cash equivalents, and short-term investments.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.